A Study to Evaluate the Efficacy and Safety of CBL-514 Compared to Placebo in Participants With Dercum's Disease Lipomas

Recruiting

Phase 2

A Study to Evaluate the Efficacy and Safety of CBL-514 Compared to Placebo in Participants With Dercum's Disease Lipomas

Sponsor:

Caliway Biopharmaceuticals Co., Ltd.

Code:

NCT06303570

Conditions

Dercum's Disease

Eligibility Criteria

Sex: All

Age: 18 - 64

Healthy Volunteers: Not accepted

Interventions

CBL-514 injection

0.9% Sodium chloride

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-06-15. This information was provided to ClinicalTrials.gov by Caliway Biopharmaceuticals Co., Ltd. on 2025-05-29.